Drug Detail

Drug Name Bevacizumab
Trade Name Avastin
Synonyms
Drug Descriptions

Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).

DrugClasses VEGF Antibody 10 VEGFR Inhibitor (Pan) 30

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Trastuzumab + Bevacizumab
DNIB0600A + Carboplatin + Bevacizumab
Bevacizumab + Temozolomide
Bevacizumab + Carmustine
Bevacizumab + Bortezomib + Temozolomide
Afatinib + Bevacizumab
MLN0128 + Bevacizumab
Anetumab ravtansine + Bevacizumab
Cisplatin + Paclitaxel + Bevacizumab + Olaparib
Atezolizumab + Bevacizumab + PGG beta-glucan
Bevacizumab + Cyclophosphamide + Sorafenib
Atezolizumab + Bevacizumab + Capecitabine
Bevacizumab + Irinotecan + SGT-53 + Temozolomide
Cyclophosphamide + Topotecan + Bevacizumab
Bevacizumab + Carboplatin
Pazopanib + Bevacizumab
Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel
Bevacizumab + INC280
S-49076 + Bevacizumab
Doxil + Bevacizamub
Bevacizumab + Fluorouracil + Oxaliplatin
Bevacizumab + Fosbretabulin
Atezolizumab + Bevacizumab + Doxil
Temsirolimus + Bevacizumab
Bevacizumab + Niraparib
Bevacizumab + Erlotinib + Temozolomide
Bevacizumab + Paclitaxel
ALT-803 + Avelumab + Bevacizumab + ETBX-011 + GI-4000
Bevacizumab + Sorafenib
Bevacizumab + CVX-060
Atezolizumab + Bevacizumab + Rucaparib Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with PD-L1-expressing advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy, advanced urothelial carcinoma ineligible for or progressed on platinum-containing therapy regardless of PD-L1 expression, and metastatic non-small cell lung cancer progressed on platinum-containing therapy (FDA.gov).
Lurbinectedin + Paclitaxel + Bevacizumab
Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Docetaxel + Fluorouracil + Epirubicin + Cyclophosphamide
Everolimus + Bevacizumab
Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab
Bevacizumab + Evofosfamide
Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid
Bevacizumab + Capecitabine + Pembrolizumab
Bevacizumab + Mirvetuximab Soravtansine
Doxorubicin + Bevacizumab
Bevacizumab + Doxorubicin + Everolimus
Bevacizumab + Carboplatin + Pembrolizumab + Olaparib
Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine
Bevacizumab + Alpha 2 Interferon
Bevacizumab + Cetuximab + Irinotecan
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
Bevacizumab + Capecitabine + Carboplatin
Avelumab + Bevacizumab + Epacadostat
Bevacizumab + Vorinostat
Bevacizumab + Emactuzumab + Paclitaxel
Bevacizumab + MEDI4736
Fluorouracil + Bevacizumab + Capecitabine + Irinotecan + Leucovorin
Bevacizumab + PRX177561
Bevacizumab + Osimertinib
Bevacizumab + Temsirolimus + Doxil
Gemcitabine + Bevacizumab + Carboplatin
Ipilimumab + Bevacizumab
Bevacizumab + Doxorubicin + Temsirolimus
Bevacizumab + Cetuximab
Bevacizumab + Marizomib
Bevacizumab + Cisplatin + Paclitaxel
Bevacizumab + FOLFIRI + PCM-075 PCM-075 inhibits PLK1, resulting in cell cycle arrest and apoptosis in cancer cells (J Clin Oncol 36, 2018 (suppl 6S; abstr 369)).
Bevacizumab + Capecitabine
Bevacizumab + VB-111
Bevacizumab + Nintedanib
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab
Bevacizumab + Tisotumab Vedotin Tisotumab vedotin is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells over expressing tissue factor (PMID: 24371232).
Bevacizumab + Fluorouracil + Leucovorin
Bevacizumab + Nivolumab
ABT-751 + Bevacizumab + Capecitabine + Irinotecan
Bevacizumab + Capecitibine + CV301 + Durvalumab
Atezolizumab + Bevacizumab
Bevacizumab + Cisplatin + Etoposide
Bevacizumab + Lomustine
Bevacizumab + Sorafenib + Temsirolimus
Sorafenib + Bevacizumab + Oxaliplatin
Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX
Altiratinib + Bevacizumab
Cobimetinib + Bevacizumab + Atezolizumab
Bevacizumab + trifluridine/tipiracil hydrochloride
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + NANT-008
Bevicizumab + DSP-7888
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Bevacizumab + Ixabepilone
Gemcitabine + Bevacizumab + Cisplatin
Neuradiab + Bevacizumab
Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab
Trebananib + Bevacizumab
Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed
Bevacizumab + Olaparib + Paclitaxel + Pembrolizumab
Nab-paclitaxel + Carboplatin + Bevacizumab
Bevacizumab + Topotecan + Paclitaxel
Atezolizumab + Bevacizumab + Exemestane
Bevacizumab + FOLFIRI
Abraxane + Bevacizumab + Erlotinib
Aldesleukin + Bevacizumab
Ad-CEA + Bevacizumab + FOLFOX
Bevacizumab + Tivantinib
Bevacizumab + TVB-2640
Bevacizumab + Abraxane
Bevacizumab + Irinotecan
Bevacizumab + Pembrolizumab
BKM120 + Bevacizumab
Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others
Cetuximab + FOLFIRI + Bevacizumab
NANT pancreatic cancer vaccine combination
Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin
Bevacizumab + SL-701
Mebendazole + Bevacizumab + Irinotecan
Bevacizumab + Docetaxel
Bevacizumab + Carboplatin + Pembrolizumab
CRLX101 + Bevacizumab
Gemcitabine + Bevacizumab + Oxaliplatin
Bevacizumab + Binimetinib + Pembrolizumab
Bevacizumab + Capecitabine + Paclitaxel
Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin
Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab
Atezolizumab + Bevacizumab + Fulvestrant
Bevacizumab + Gemcitabine + Nab-paclitaxel
Bevacizumab + Niraparib + TSR-042
FABLOx
Bevacizumab + Reolysin
FANG vaccine + Bevacizumab
Bevacizumab + Telatinib
Bevacizumab + Cediranib
Avastin + Doxorubicin + Docetaxel
Bevacizumab + Veliparib
Bevacizumab + Vinblastine
Capecitabine + Oxaliplatin + Bevacizumab
Bevacizumab Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).
Bevacizumab + Cannabidiol + FOLFIRINOX
Bevacizumab + Plerixafor
Bevacizumab + Carboplatin + Durvalumab + Paclitaxel
ABBV-399 + Bevacizumab
Bevacizumab + Erlotinib + Gemcitabine
Bevacizumab + Rucaparib
Bevacizumab + MINT1526A
Temozolomide + Irinotecan + Bevacizumab
Bevacizumab + Cyclophosphamide + Pembrolizumab
Gemcitabine + Bevacizumab
Bevacizumab + Paclitaxel + Pembrolizumab
Abraxane + Temozolomide + Bevacizumab
Bevacizumab + Cyclophosphamide + Zoledronic acid
Bevacizumab + Brentuximab vedotin
Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel
Bevacizumab + FOLFOX
Bevacizumab + Napabucasin
Bevacizumab + Carboplatin + Paclitaxel
Temsirolimus + Bevacizumab + Cetuximab
Bevacizumab + FOLFIRINOX
Atezolizumab + Bevacizumab + Tamoxifen
Bevacizumab + Durvalumab + Olaparib
Bevacizumab + Nab-Rapamycin
Bevacizumab + Pemetrexed
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
Bevacizumab + Carboxyamidotriazole Orotate
Bevacizumab + MEDI4736 + Tremelimumab
RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab
Bevacizumab + MEDI3617
Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel
Bevacizumab + Capecitabine + Temozolomide
Atezolizumab + Entinostat + Bevacizumab
sEphB4-HSA + Bevacizumab
Bevacizumab + FOLFOX + Nab-Rapamycin
Axitinib + Bevacizumab
Atezolizumab + Bevacizumab +Peg-interferon alfa-2a
Abaloparatide + Bevacizumab Abaloparatide (Tymlos) is a peptide analog of human parathyroid hormone-related protein (PTHrP), which stimulates bone formation and potentially increases bone mineral density (PMID: 25393645, PMID: 29260289). Abaloparatide (Tymlos) is approved for osteoporosis (FDA.gov).
Bevacizumab + Erlotinib
Bevacizumab + Carotuximab
Bevacizumab + Dexamethasone + Evofosfamide